Hemophilia Gene Therapy - A Pipeline Analysis Report
Shire became the biggest hemophilia player after it bought Baxalta in June 2016, and the company reported total hemophilia revenue of $870.9 million in the FY2016.
(EMAILWIRE.COM, October 31, 2017 ) Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing or defective factor VIII. Most individuals, roughly 85%, have hemophilia A and produce too little or no factor VIII. On the other hand, hemophilia B, which is also called Christmas disease, is caused by a deficiency of factor IX.
Request sample copy of the report at: http://www.orbisresearch.com/contacts/request-sample/497964
Covered in this report
The report covers the present scenario and the growth prospects of the hemophilia gene therapy. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The report also includes a discussion of the key companies operating in this market.
Major companies
uniQure
Alnylam Pharmaceuticals
BioMarin Pharmaceutical
Spark Therapeutics
Shire
Research Hemophilia Gene Therapy - A Pipeline Analysis Report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period.
Key questions answered in this report
How will the market evolve during the forecast period?
What are the major parameters impacting the market?
What are the key market trends?
What are the challenges to market growth?
Who are the key companies in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Companies Mentioned:
uniQure, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Spark Therapeutics, and Shire.
Table of Contents:
PART 01: EXECUTIVE SUMMARY
PART 02: RESEARCH METHODOLOGY
PART 03: HEMOPHILIA GENE THERAPY: AN INSIGHT
PART 04: MAJOR REGULATORY AUTHORITIES
PART 05: PIPELINE LANDSCAPE
PART 06: COMPARATIVE ANALYSIS
PART 07: INDICATION ANALYSIS
PART 08: THERAPEUTIC ASSESSMENT BY THERAPY
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: THERAPEUTIC ASSESSMENT BY STAGE AND ROA
PART 11: KEY COMPANIES
PART 12: APPENDIX
Enquire more details of the report at: http://www.orbisresearch.com/contact/purchase/497964
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Request sample copy of the report at: http://www.orbisresearch.com/contacts/request-sample/497964
Covered in this report
The report covers the present scenario and the growth prospects of the hemophilia gene therapy. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The report also includes a discussion of the key companies operating in this market.
Major companies
uniQure
Alnylam Pharmaceuticals
BioMarin Pharmaceutical
Spark Therapeutics
Shire
Research Hemophilia Gene Therapy - A Pipeline Analysis Report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period.
Key questions answered in this report
How will the market evolve during the forecast period?
What are the major parameters impacting the market?
What are the key market trends?
What are the challenges to market growth?
Who are the key companies in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Companies Mentioned:
uniQure, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Spark Therapeutics, and Shire.
Table of Contents:
PART 01: EXECUTIVE SUMMARY
PART 02: RESEARCH METHODOLOGY
PART 03: HEMOPHILIA GENE THERAPY: AN INSIGHT
PART 04: MAJOR REGULATORY AUTHORITIES
PART 05: PIPELINE LANDSCAPE
PART 06: COMPARATIVE ANALYSIS
PART 07: INDICATION ANALYSIS
PART 08: THERAPEUTIC ASSESSMENT BY THERAPY
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: THERAPEUTIC ASSESSMENT BY STAGE AND ROA
PART 11: KEY COMPANIES
PART 12: APPENDIX
Enquire more details of the report at: http://www.orbisresearch.com/contact/purchase/497964
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results